Roles of the WWOX in pathogenesis and endocrine therapy of breast cancer

Exp Biol Med (Maywood). 2015 Mar;240(3):324-8. doi: 10.1177/1535370214561587. Epub 2014 Dec 4.

Abstract

Breast cancer is one of the most common malignancies, often with complicated etiology and poor clinical outcome. In recent years, a critical role has emerged for the WW domain-containing oxidoreductase (WWOX) in breast cancer. WWOX is a tumor suppressor; it is deleted or attenuated in 29-63.2% of breast cancer tissues and is associated with a poor prognosis of breast cancer patients. WWOX heterozygous knockout mice show a higher incidence of mammary tumors and impaired branching morphogenesis. At the molecular level, WWOX interacts with AP2γ, ErbB4, SMAD3, and WBP2 suppressing their transcription activities in breast cancer cell lines. This review provides comprehensive insights into the current knowledge of WWOX activities in the pathogenesis and endocrine therapy of breast cancer.

Keywords: WW domain-containing oxidoreductase; breast cancer; endocrine therapy; tumorigenesis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Biomarkers, Tumor / physiology
  • Breast Neoplasms / etiology*
  • Breast Neoplasms / physiopathology
  • Breast Neoplasms / therapy*
  • Carcinogenesis
  • Disease Models, Animal
  • Disease Progression
  • Female
  • Humans
  • Mice
  • Oxidoreductases / physiology*
  • Prognosis
  • Selective Estrogen Receptor Modulators / therapeutic use*
  • Tamoxifen / therapeutic use
  • Tumor Suppressor Proteins / physiology*
  • WW Domain-Containing Oxidoreductase

Substances

  • Antineoplastic Agents, Hormonal
  • Biomarkers, Tumor
  • Selective Estrogen Receptor Modulators
  • Tumor Suppressor Proteins
  • Tamoxifen
  • Oxidoreductases
  • WW Domain-Containing Oxidoreductase
  • WWOX protein, human